Home・Lista de Ações・Relay Therapeutics Inc

Relay Therapeutics Inc

Fechado

SetorSaúde

19.61 -0.15

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

18.48

Máximo

19.8

Indicadores-chave
By Trading Economics
Rendimento	-18M -73M
Vendas	-4M 3M
EPS	-0.41
Margem de lucro	-2,443.033
Funcionários	193
EBITDA	-15M -73M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+28.1% upside

Dividendos
By Acuity
Próximos Ganhos	5 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1.6B 4.1B
Abertura anterior	19.76
Fecho anterior	19.61

Sentimento de Notícias

By Acuity

50%

168 / 340 Ranking em Healthcare

Relay Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de ago. de 2026, 23:02 UTC

News

Relay Therapeutics shares are lower in after-market hours following disappointing Q2 results, including a net loss of $83.7 million and revenue of $350,000.

5 de ago. de 2026, 22:26 UTC

Relay Therapeutics Inc. shares advanced in after-market trading, maintaining a position above its 20-day moving average amid broader macroeconomic sentiment.

4 de ago. de 2026, 19:26 UTC

Correlated Moves

Relay Therapeutics Inc is trading higher during Tuesday's session, continuing its upward trend since Monday's close. Broader market sentiment supports this performance.

3 de ago. de 2026, 21:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, continuing a downward trend amid three consecutive sessions of declines and no specific news.

31 de jul. de 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower in Friday's session, reflecting broader declines in the biotech sector amid rising yields and inflation concerns.

30 de jul. de 2026, 17:36 UTC

Correlated Moves

News

Relay Therapeutics Inc is rising as it advances its PI3Kα inhibitor for breast cancer treatment, drawing renewed interest and nearing IPO levels.

29 de jul. de 2026, 19:36 UTC

Macro Event

Relay Therapeutics Inc shares are higher Wednesday, supported by increased trading volume and recent Federal Reserve decisions on interest rates.

28 de jul. de 2026, 18:06 UTC

Relay Therapeutics Inc. shares are lower today amid broader market declines, influenced by significant drops in Asian indices and concerns in the semiconductor sector.

27 de jul. de 2026, 19:56 UTC

Relay Therapeutics Inc. is trading higher, reaching a peak earlier in the session, despite no specific news driving the increase.

22 de jul. de 2026, 15:46 UTC

Correlated Moves

Relay Therapeutics shares are lower following first-quarter results, which showed a modest decline. The Russell 2000 Index's decrease may also be influencing performance.

21 de jul. de 2026, 21:51 UTC

Relay Therapeutics Inc shares are higher in after-market trading, reflecting strong momentum amid renewed interest in technology stocks, particularly those related to AI.

20 de jul. de 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc. is trading lower amid notable volatility, reflecting broader market declines alongside a drop in the ARK Genomic Revolution ETF.

Comparação entre Pares

Variação de preço

Relay Therapeutics Inc Previsão

Preço-alvo

By TipRanks

28.1% parte superior

Previsão para 12 meses

Média 25.3 USD 28.1%

Máximo 31 USD

Mínimo 20 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Relay Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

12 ratings

Comprar

Manter

Vender

Com base em 12 analistas que deram avaliações de ações para Relay Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

168 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.